Pheochromocytomas and Paragangliomas Market Size is projected to grow at a CAGR of 8.60% by 2034, estimates DelveInsight

DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of PCPG, historical and forecasted epidemiology as well as Pheochromocytomas and Paragangliomas therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore Pheochromocytomas/Paragangliomas Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Pheochromocytomas/Paragangliomas Market Report
• In November 2025, Merck Sharp & Dohme LLC initiated a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
• In November 2025, Perspective Therapeutics conducted a study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors. This is a prospective, multi-center, open-label, radioactivity dose-finding/ dose expansion study of [212Pb]VMT-α-NET in up to 260 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT).
• The Pheochromocytomas and Paragangliomas market size in the 7MM is expected to grow from USD 314 million in 2025 to USD 662 million in 2034.
• The total number of Pheochromocytomas and Paragangliomas incident cases in the 7MM was nearly 4,900 cases in 2024 and is projected to increase during the forecasted period.
• In 2024, it has been observed that germline/somatic mutations are present in nearly 75% of all the cases in the US.
• The total number of PCPG incident cases in EU4 and the UK was estimated to be nearly 1,800 cases in 2024.
• Among EU4 and the UK, Germany accounted for the highest number of incident cases of pheochromocytoma and paraganglioma, while Spain had the least number of cases, in 2024.
• Among the stage-specific cases, the number of localized PCPG cases was higher than that of metastatic cases in Japan.
• The leading Pheochromocytomas/Paragangliomas Companies such as CHIMERIX, OHARA Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
• Promising Pheochromocytomas/Paragangliomas Therapies such as Lanreotide, Axitinib, Sunitinib, Ultratrace Iobenguane (MIBG) I 131, Cabozantinib 40 mg, Belzutifan, melphalan and others.

Strategise your business goals by understanding market dynamics @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pheochromocytomas/Paragangliomas Overview
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors arising from chromaffin cells, with pheochromocytomas originating in the adrenal medulla and paragangliomas developing from extra-adrenal sympathetic or parasympathetic paraganglia. These tumors are characterized by excessive or episodic secretion of catecholamines such as epinephrine, norepinephrine, and dopamine, leading to clinical manifestations that commonly include persistent or paroxysmal hypertension, severe headaches, palpitations, diaphoresis, anxiety, and tachycardia, although some paragangliomas may be nonfunctional.

Pheochromocytomas/Paragangliomas Epidemiology Segmentation in the 7MM
• Pheochromocytomas and paragangliomas Incident Cases
• Pheochromocytomas and paragangliomas Occurrence or Absence of mutation
• Pheochromocytomas and paragangliomas Age-specific Cases
• Pheochromocytomas and paragangliomas Stage-specific Cases

Visit for more about Pheochromocytomas/Paragangliomas Prevalence @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pheochromocytomas and Paragangliomas Marketed Drugs
• DEMSER Capsule 250 mg (metyrosine): Bausch Health and Ono Pharmaceutical
DEMSER is a promising drug with efficacy in the improvement of the symptoms in patients who are not able to sufficiently control the symptoms with sympatholytic drugs. DEMSER is indicated in the treatment of pheochromocytoma patients for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of malignant pheochromocytoma patients. DEMSER (ONO-5371) was approved and launched in the United States in 1979 for the treatment of pheochromocytoma. In January 2019, Ono Pharmaceutical received manufacturing and marketing approval in Japan for DEMSER capsule for improvement of the status of catecholamine excess secretion in pheochromocytoma patients. In July 2020, the US FDA approved Amneal Pharmaceuticals' generic version of DEMSER (metyrosine) oral capsules. Amneal's generic is the first for DEMSER to be approved in the United States.

Pheochromocytomas and Paragangliomas Emerging Drugs
• ONC201: Chimerix
ONC201, also called dordaviprone, is a first-in-class small-molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP. ONC201 has been evaluated in an open-label Phase II investigator-initiated study that treated 30 patients at the Cleveland Clinic with rare neuroendocrine tumors. Paraganglioma patients were enrolled in two cohorts initiating ONC201 either once or twice weekly. ONC201 interim efficacy results in dopamine-secreting tumors outside the brain showed 50% ORR in paraganglioma. Investigator-assessed data from this study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2021 and published in the journal Clinical Cancer Research in 2022.

• WELIREG (belzutifan/MK-6482): Merck
WELIREG is a novel, potent and selective inhibitor of HIF-2a. WELIREG is indicated for von Hippel-Lindau (VHL) disease who need treatment for a type of kidney cancer called Renal Cell Carcinoma (RCC), tumors in the brain and spinal cord called Central Nervous System (CNS) hemangioblastomas, or a type of pancreatic cancer called pancreatic Neuroendocrine Tumors (pNET), that do not require surgery right away, and kidney cancer that has spread (advanced RCC) following treatment with a PD-1 or PD-L1 and VEGF cancer medicines. It is currently being evaluated in Phase II for the treatment of advanced PCPG, with a target action date of May 26, 2025, under the Prescription Drug User Fee Act (PDUFA).

For more information, visit Pheochromocytomas and Paragangliomas Medication and Companies @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pheochromocytomas and Paragangliomas Companies
CHIMERIX, OHARA Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.

Scope of the Pheochromocytomas and Paragangliomas Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Pheochromocytomas/Paragangliomas Companies- CHIMERIX, OHARA Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
• Pheochromocytomas/Paragangliomas Therapies- Lanreotide, Axitinib, Sunitinib, Ultratrace Iobenguane (MIBG) I 131, Cabozantinib 40 mg, Belzutifan, melphalan and others.
• Pheochromocytomas/Paragangliomas Therapeutic Assessment: Pheochromocytomas/Paragangliomas current marketed and Pheochromocytomas/Paragangliomas emerging therapies
• Pheochromocytomas/Paragangliomas Market Dynamics: Pheochromocytomas/Paragangliomas market drivers and Pheochromocytomas/Paragangliomas market barriers
• Pheochromocytomas/Paragangliomas Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pheochromocytomas/Paragangliomas Unmet Needs, KOL's views, Analyst's views, Pheochromocytomas/Paragangliomas Market Access and Reimbursement

Do you know the treatment paradigms for different countries? Download our Pheochromocytomas and Paragangliomas Treatment Market- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. PCPG MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. EPIDEMIOLOGY AND MARKET METHODOLOGY
7. PCPG BACKGROUND AND OVERVIEW
8. PCPG TREATMENT AND MANAGEMENT
9. PCPG EPIDEMIOLOGY AND PATIENT POPULATION
10. PCPG PATIENT JOURNEY
11. PCPG MARKETED DRUGS
12. PCPG DISCONTINUED PRODUCT
13. PCPG EMERGING DRUGS
14. PCPG: SEVEN MAJOR MARKET ANALYSIS
15. PCPG UNMET NEEDS
16. SWOT ANALYSIS
17. KOL VIEWS
18. MARKET ACCESS AND REIMBURSEMENT
19. APPENDIX
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.